Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Apatinib with HAIC for Resectable Intrahepatic Cholangiocarcinoma
NCT06296563Phase 2Recruiting
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in intrahepatic cholangiocarcinoma (ICC). Started Mar 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06296563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06296563.